跳至主要内容
临床试验/CTRI/2020/05/025058
CTRI/2020/05/025058尚未招募不适用

An exploratory clinical trial to evaluate role of Chandrashoor(Lepidium sativum Linn.) Ladu in Kashtartava(Primary Dysmenorrhea) as Shoolaghna.

CARC1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2020年3月11日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
40
试验地点
1
主要终点
To evaluate role of chandrashoor Ladu in minimising spasmodic pain caused by kashtartava(primary dysmenorrhea).

研究概览

简要总结

  1. Primary dysmenorrhea is the commnest among menstruation related conditions. There are chances of increase in prevalence of primary dysmenorrhea in future due to consistently changing lifestyle.

  2. Currently available treatment for dysmenorrhea includes use of NSAIDs, oral contraceptive medications, prostaglandin synthetase inhibitors ; if taken for longer periods may shoew potential side effects. While Ayurvedic treatments like pichu, swedana, basti etc. are not always feasible for patients.

  3. Hence there is a need to find an easy solution. Adding certain food preparations in diet can improve the condition. Literature and previous study have proved effectiveness of Chaturbeeja (a set of four seeds) in relieving spasmodic pain.Chandrashoor ( Lepidium sativum Linn.) is one of content of Chaturbeeja.

  4. Therefore this study will assess effect of Chandrashoor ( Lepiduim sativum Linn.) to relieve spasmodic pain of primary dysmenorrhea and minimize associated symptoms if added in diet in the form of ladu.

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Not Applicable

入排标准

年龄范围
15.00 Year(s) 至 28.00 Year(s)(—)
性别
Female

入选标准

  • 1.Patients with chief complaint of painful menses and associated symptoms at least for three cycles.
  • 2.Patients with pain for at least for first 2 days of the cycle.
  • 3.Nulliparous females.
  • 4.Age group-15 to 28 years irrespective of caste and religion.

排除标准

  • 1.Patients with chronic illness for example, DM and any systemic disorder.
  • 2.Any diagnosed uterine pathology (Menorrhagia,Fibroid,Adenomycosis, Endometriosis).
  • 3.Patients undergoing hormonal treatment for Dysmenorrhea.
  • 4.Patients with Pitta Prakruti.
  • 5.Patients with heavy menstrual bleeding.

结局指标

主要结局

To evaluate role of chandrashoor Ladu in minimising spasmodic pain caused by kashtartava(primary dysmenorrhea).

时间窗: 2 months

次要结局

  • To evaluate role of Chandrashoor Ladu in minimising Kashtartava(primary dysmenorrhea) associated symptoms.(2 months)

研究者

发起方
CARC
申办方类型
Private medical college

研究点 (1)

Loading locations...

相似试验